124 related articles for article (PubMed ID: 8055457)
1. Predictive parameters of biologic behavior of early stage nonseminomatous testicular germ cell tumors.
de Riese WT; Albers P; Walker EB; Ulbright TM; Crabtree WN; Reister T; Foster RS; Donohue JP
Cancer; 1994 Aug; 74(4):1335-41. PubMed ID: 8055457
[TBL] [Abstract][Full Text] [Related]
2. Predictive parameters in biologic assessment of low-stage retroperitoneal lymph-node dissection.
Albers P; deRiese W; Walker EB; Ulbright TM; Crabtree WN; Reister T; Foster RS; Donohue JP
World J Urol; 1994; 12(3):120-4. PubMed ID: 7951336
[TBL] [Abstract][Full Text] [Related]
3. Quantitative DNA measurement by flow cytometry and image analysis of human nonseminomatous germ cell testicular tumors.
de Riese W; Walker EB; de Riese C; Ulbright TM; Crabtree WN; Messemer J; Jones JA; Hinkel A; Foster RS; Donohue JP
Urol Res; 1994; 22(4):213-20. PubMed ID: 7871632
[TBL] [Abstract][Full Text] [Related]
4. Tumor proliferative activity is predictive of pathological stage in clinical stage A nonseminomatous testicular germ cell tumors.
Albers P; Ulbright TM; Albers J; Miller GA; Orazi A; Crabtree WN; Baniel J; Reister T; Sidner RA; Foster RS; Donohue JP
J Urol; 1996 Feb; 155(2):579-86. PubMed ID: 8558664
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage A nonseminomatous testicular germ cell tumor at low risk for occult metastasis.
Albers P; Miller GA; Orazi A; Ulbright TM; Albers J; Donohue JP; Foster RS
Cancer; 1995 Feb; 75(3):844-50. PubMed ID: 7828136
[TBL] [Abstract][Full Text] [Related]
6. Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer.
Moul JW; McCarthy WF; Fernandez EB; Sesterhenn IA
Cancer Res; 1994 Jan; 54(2):362-4. PubMed ID: 8275469
[TBL] [Abstract][Full Text] [Related]
7. Flow-cytometric and quantitative histologic parameters as prognostic indicators for occult retroperitoneal disease in clinical-stage-I non-seminomatous testicular germ-cell tumors.
De Riese WT; De Riese C; Ulbright TM; Walker EB; Messemer J; Jones JA; Reister T; Albers P; Allhoff EP; Foster RS
Int J Cancer; 1994 Jun; 57(5):628-33. PubMed ID: 8194868
[TBL] [Abstract][Full Text] [Related]
8. A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only.
Nicolai N; Miceli R; Artusi R; Piva L; Pizzocaro G; Salvioni R
J Urol; 2004 Jan; 171(1):172-6. PubMed ID: 14665870
[TBL] [Abstract][Full Text] [Related]
9. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW
Cancer; 1998 Sep; 83(5):1002-11. PubMed ID: 9731905
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of nuclear DNA ploidy pattern in nonseminomatous germ cell testicular tumors.
Nativ O; Winkler HZ; Farrow GM; Therneau TM; Lieber MM
Urology; 1994 Feb; 43(2):197-202. PubMed ID: 8116115
[TBL] [Abstract][Full Text] [Related]
11. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group.
Heidenreich A; Albers P; Hartmann M; Kliesch S; Kohrmann KU; Krege S; Lossin P; Weissbach L;
J Urol; 2003 May; 169(5):1710-4. PubMed ID: 12686815
[TBL] [Abstract][Full Text] [Related]
12. MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis.
Albers P; Bierhoff E; Neu D; Fimmers R; Wernert N; Müller SC
Cancer; 1997 May; 79(9):1710-6. PubMed ID: 9128986
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.
Moul JW; Foley JP; Hitchcock CL; McCarthy WF; Sesterhenn IA; Becker RL; Griffin JL
J Urol; 1993 Sep; 150(3):879-83. PubMed ID: 8393944
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors.
Heidenreich A; Schenkmann NS; Sesterhenn IA; Mostofi FK; McCarthy WF; Heidenreich B; Moul JW
J Urol; 1997 Aug; 158(2):620-5. PubMed ID: 9224380
[TBL] [Abstract][Full Text] [Related]
16. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
Beck SD; Foster RS; Bihrle R; Donohue JP
Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial.
Albers P; Siener R; Kliesch S; Weissbach L; Krege S; Sparwasser C; Schulze H; Heidenreich A; de Riese W; Loy V; Bierhoff E; Wittekind C; Fimmers R; Hartmann M;
J Clin Oncol; 2003 Apr; 21(8):1505-12. PubMed ID: 12697874
[TBL] [Abstract][Full Text] [Related]
18. Automated image analysis DNA cytometry to predict the pathological stage in clinical stage I nonseminomatous testicular germ cell tumors.
Albers P; Burger RA; Braun MH; Fichtner J; Fisch M; Stöckle M
Eur Urol; 1997; 31(3):356-9. PubMed ID: 9129931
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of P53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease.
Lewis DJ; Sesterhenn IA; McCarthy WF; Moul JW
J Urol; 1994 Aug; 152(2 Pt 1):418-23. PubMed ID: 8015085
[TBL] [Abstract][Full Text] [Related]
20. Retroperitoneal lymph node dissection in patients with high risk testicular cancer.
Williams SB; McDermott DW; Dock W; Bahnson E; Berry AM; Steele GS; Richie JP
J Urol; 2009 May; 181(5):2097-101; discussion 2101-2. PubMed ID: 19286227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
